Zai Lab Limited

Zai Lab Limited is a patient-focused, innovative, commercial-stage global biopharmaceutical company. Its core business involves discovering, developing, and commercializing best-in-class and first-in-class therapies for medical conditions with significant unmet needs, particularly in oncology, immunology, neuroscience, and infectious diseases. The company's mission is to leverage its expertise and resources to advance science from the lab to patients' lives. Zai Lab maintains dual headquarters in Cambridge, Massachusetts, USA, and Shanghai, China.

Zai Lab's business model combines in-licensed assets with strategic partnerships and in-house development capabilities. The company has successfully commercialized several products in China, including Zejula® (niraparib) for ovarian cancer, Optune® (Tumor Treating Fields) for glioblastoma and mesothelioma, Qinlock® (ripretinib) for gastrointestinal stromal tumor (GIST), Nuzyra® (omadacycline) for bacterial infections, Augtyro™ (repotrectinib) for NSCLC and NTRK-positive solid tumors, and Vyvgart® (efgartigimod) for generalized myasthenia gravis. Its global pipeline includes investigational therapies such as zocilurtatug pelitecan (zoci), a DLL3-targeted antibody-drug conjugate for small cell lung cancer and extrapulmonary neuroendocrine carcinomas, and ZL-1503, a bispecific IL-13/IL-31 antibody for atopic dermatitis.

Founded in 2014 by Dr. Samantha Du, who serves as Founder, Chairperson, and Chief Executive Officer, Zai Lab aims to become a leading global biopharma company. Recent developments include receiving EMA Orphan Drug Designation for zocilurtatug pelitecan (zoci) in pulmonary neuroendocrine carcinomas and China NMPA approval for TIVDAK® (tisotumab vedotin) for recurrent or metastatic cervical cancer in June 2026. The company also announced changes to its senior leadership team in May 2026, including the departure of its President and COO. Zai Lab is actively expanding its global presence, particularly in the U.S. market, while continuing to leverage its strong commercial infrastructure in China.